Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Genetic testing company Fulgent Genetics nets $40.4mm in IPO

Executive Summary

Fulgent Genetics Inc. (NGS and genetic testing) netted $40.4mm in its IPO of 4.8mm (including full exercise of the 630k overallotment) shares at $9 (below its planned $12-14 range).
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
      • Genomics-Proteomics
    • Gene Therapy, Cell Therapy
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Laboratory Testing Services
Deal Status
  • Final
Deal Type
  • Financing
    • IPO

Related Companies